home / stock / prqr / prqr news

PRQR News and Press, ProQR Therapeutics N.V. From 02/07/22

Stock Information
Company Name: ProQR Therapeutics N.V.
Stock Symbol: PRQR
Market: NASDAQ
Website: proqr.com
Menu
PRQR PRQR Quote PRQR Short PRQR News PRQR Articles PRQR Message Board
Get PRQR Alerts

News, Short Squeeze, Breakout and More Instantly...
PRQR - ProQR to Present at Upcoming SVB Leerink Conference

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 07, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Compa...
PRQR - Catalyst Watch for next week: Eyes on Uber, Hertz, Amgen, Peloton and AMD

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

PRQR - RIDE, RKLB and CLLS among pre market gainers

AMC Entertainment Holdings (NYSE:AMC) +14% as preliminary Q4 revenue tops consensus. Wallbox (NYSE:WBX) +14% Uber and Wallbox to expand partnership to all of the U.S. Spire Global (NYSE:SPIR) +10% as preliminary Q4 revenue soars 111% Y/Y. ObsEva (NASDAQ:OBSV) +9%. ProQR Th...

PRQR - ProQR Announces Last Patient Has Completed 12 Month Visit in Phase 2/3 Illuminate Trial of Sepofarsen

Top-line data now expected to be announced in Q1 2022 Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR ...
PRQR - ProQR Announces Amendment to Convertible Debt Financing Agreement with Pontifax Ventures and Kreos Capital

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) (“ProQR”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that it has ...

PRQR - Dosing underway in ProQR Therapeutics' late-stage QR-421a trial for retinitis pigmentosa

ProQR Therapeutics (NASDAQ:PRQR) announces that the first patient has been dosed in Phase 2/3 Sirius and Celeste clinical trials of RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome. RP and Usher syndrome associated with USH2A are inherited retina...

PRQR - ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/...
PRQR - ProQR Announces Highlights from Analyst Event

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Ana...

PRQR - ProQR to Webcast Virtual Analyst Event on November 18

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, will webcast a virtual Ana...

PRQR - ProQR Announces Upcoming Investor Conferences in November and December

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Compa...
Previous 10 Next 10